cp094 has been researched along with methyl 5-aminolevulinate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campbell, S; Curnow, A; Pye, A | 1 |
| Curnow, A; Dodd, NJF; Dogra, Y; Ferguson, DCJ; Smerdon, GR; Winyard, PG | 1 |
1 trial(s) available for cp094 and methyl 5-aminolevulinate
| Article | Year |
|---|---|
Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Cell Line, Tumor; Humans; In Vitro Techniques; Iron Chelating Agents; Middle Aged; Photochemotherapy; Photosensitizing Agents; Pilot Projects; Protoporphyrins; Pyridones; Skin Neoplasms | 2008 |
1 other study(ies) available for cp094 and methyl 5-aminolevulinate
| Article | Year |
|---|---|
The hydroxypyridinone iron chelator CP94 increases methyl-aminolevulinate-based photodynamic cell killing by increasing the generation of reactive oxygen species.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Cell Survival; Histidine; Humans; Iron Chelating Agents; Metalloporphyrins; Photochemotherapy; Photosensitizing Agents; Protoporphyrins; Pyridones; Reactive Oxygen Species | 2016 |